TDC
UTHR icon

Thompson Davis & Co’s United Therapeutics UTHR Stock Holding History

Thompson Davis & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,500
Closed -$283K – 859
2013
Q4 		$283K Buy
+2,500
New +$225K 0.43% 56

Other funds holding UTHR

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Thompson Davis & Co's UTHR Position: Q1 2014 in Review

Thompson Davis & Co sold out of United Therapeutics (UTHR) in Q1 2014, closing a stake of 2,500 shares — an estimated $283K sold.

Thompson Davis & Co first reported a position in UTHR in Q4 2013 and held it in 1 quarter. The position peaked at $283K in Q4 2013. 308 funds tracked by Wall St. Rank hold UTHR as of Q1 2014.

  • Thompson Davis & Co reported no remaining United Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 2,500 United Therapeutics shares in Q1 2014, an estimated $283K.
  • Thompson Davis & Co first reported a position in United Therapeutics in Q4 2013 and held it in 1 quarter.
  • Thompson Davis & Co's United Therapeutics position peaked at $283K in Q4 2013.
  • 308 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2014.

Based on Thompson Davis & Co's 13F filing for Q1 2014, filed 9 May 2014.